Allar frslur Allir flokkar Sos Um flagi rskrning Lg Spjallid@Vantru Pstfang Vantru@Facebook Vantru@Youtube Vantru@Twitter

Jen Fe heilsuplsturinn er pramdasvindl

Ef orinu plstur er skipt t fyrir drykkur, duft, mansjrusveppur ea eitthva lka hljmar eftirfarandi auglsing ansi kunnulega:

Loksins er fanlegur slandi essi frbri heilsuplstur. 100% nttruleg innihaldsefni, engin aukaefni! Ef e- af eftirfarandi vi ig gtum vi hjlpa r! arftu a lttast, vantar ig aukna orku, viltu minnka sykurrfina og f jafnari blsykur yfir daginn, ertu me svefntruflanir, viltu koma jafnvgi lkamsstarfsemina heilbrigan og nttrulegan htt!

etta er nstum v of gott til ess a vera satt! Reyndar arf ekki a leita lengi netinu til ess a sj a etta er ekki allur sannleikurinn (1). Framleiandinn er ar m.a. gagnrndur fyrir a gefa ekki fullngjandi upplsingar um innihaldsefni plstranna og rannsknir virkni eirra. Gullld heilsuplstranna var fyrir 15 rum san en enn streitast fyrirtki vi a koma eim marka.

Jen Fe plsturinn er ekkert einsdmi v fyrir eru markanum tal heilsuvrur sem eiga a lkna alls konar kvilla. Sjaldan er vsa til rannskna heldur eru jkvir vitnisburir ltnir ngja um gagnsemi vrunnar (allir kringum mig voru a lttast...bla bla bla...).

a er eftir miklu a slgjast ef framleiandanum tekst a koma vru sinni tsku. Slufyrirkomulag plstranna er dmigert pramdafyrirkomulag ar sem dreifingarailinn arf a borga flgur fjr fyrir a komast inn slukerfi og grir ekkert fyrr en hann er kominn me harduglega slumenn fyrir nean sig kejunni (2).

ess m a lokum geta a ver hj vefverslun framleiandans Bandarkjun er yfir 7.000 kr. (69$) fyrir mnaarskammt af drari gerinni en drari gerin (Power Patch) kostar yfir 12.000 kr. (120$) mnui.

Sverrir Gumundsson 27.10.2008
Flokka undir: ( Kjaftisvaktin )

Vibrg


Helgi D. - 27/10/08 11:13 #

g myndi n kynna mr mli betur ur en dmir vruna. Konan mn er einmitt a nota essa plstra (er ekki a selja , bara neytandi) og vlkur munur segir hn. Eftir barnsbur hefur hn veri afar slm skrokknum samt v a liagigt hefur leiki hana grtt. Eftir miki lkamlegt pl, eins og t.d. lkamsrkt og langar gngur sem dmi hefur hn veri handnt skrokknum og urft a leita sjkrajlfun og nudd til a halda sr gri, sem er talsvert drara en notkun plstrunum. Bara me v a nota essa plstra hafa verkirnir horfi. Hvort sem a eru plstrarnir ea hva finnst henni a alveg 12 sund krna viri a sleppa vi mikla verki og har upphir sjkrajlfun og nudd hverjum mnui.......

Hva markashugmyndina varar m a sjlfsgu deila um.....En plstrarnir hafa allavega breytt miklu fyrir hana....


Jn Magns (melimur Vantr) - 27/10/08 11:58 #

Svolti fyndi a greininni stendur:

Sjaldan er vsa til rannskna heldur eru jkvir vitnisburir ltnir ngja um gagnsemi vrunnar (allir kringum mig voru a lttast...bla bla bla...).

og Helgi D. kemur me nkvmlega svona vitnisbur sem a sanna a etta s alveg rosalega gott en ekki einhva kjafti. Helgi, mttir vsa einhverjar rannsknir ef veist um einhverjar. Vi hr Vantr tkum ekki mark vitnisburum v a hefur sanna sig margoft a a er ekkert a marka .

San vil g spyrja hva a er sem gerir essa plstra svona "lknandi"?


Helgi D. - 27/10/08 14:59 #

g fann mig bara kninn til a commenta fyrst a konan er binn a vera a prfa etta.

g ekki ennan plstur rauninni ekki baun, fkk hann hendurnar fyrir tveimur vikum og tti a lta konuna prfa etta. g hef sjlfur ekkert kynnt mr mli en langai bara svona a varpa ljsi etta, ar sem konan hefur ekki lagt a vana sinn a ljga a mr :) ar sem hn segir hann svnvirka....

Annars er vafalti hgt a grafa upp einhverjar rannsknir varandi gagnsemina essu, g reikna allavega svona fastlega me v a eir styji sig vi einhverjar rannsknir eir sem eru a framleia etta. g arf a sj hvort g finni ekki eitthva og svo skal g psta v hrna


Helgi D. - 27/10/08 15:16 #

Clinical Study Summary Jen Fe Patch

etta var svona a sem g fann fljtu bragi.....Virist allavega vera einhverjar rannsknir a finna ef googlar etta.....Er ekki annars best a prfa etta bara sjlfur ur en maur dmir??

Clinical Study Summary Jen Fe Patch

A synopsis of the 12-week, randomized,double-blind, placebo-controlled study on the effects of the Nexagen USA Jen Fe Patch on weight loss, waist circumference, resting metabolic rate and body composition.

In a one year study starting in December 2005, Nexagen USA subjected its Jen Fe Next patch to the most rigorous form of testing in the universe of clinical research - a methodology beyond reproach that is considered by industry experts to be the 'Gold Standard' for scientific evaluation.

The 12-week trial was conducted to objectively compare the effects on weight loss, resting metabolic rate and body composition that result when the Jen Fe Next patch is used relative to when it is not used. The desired result of this study was an objective, quantitative evaluation . It was therefore critically important that only the most highly regarded and reliable of scientific testing methods be used. Anything short of this may have produced a result that would fail to be objective, fail to be scientifically viable or leave some room for doubt about the effectiveness of the Jen Fe Next patch. It became clear early on that removing all doubt was necessary to the objective at hand, and would require the use of a randomized, double-blind, placebo controlled testing environment .

To fully understand the importance of using this specific type of test, it's important to understand the individual elements of the test, what each one means and how each served to fortify the integrity of the testing environment.

A randomized sample, as it relates to scientific testing, is one in which every part of the sample group has in identical chance of being selected any time a selection is made from the entire sample. To be a truly random, the only variable that can be present at the time of selection is chance.

In the case of the Jen Fe trial, random selections were made from an original group of one hundred obese or overweight subjects. The original one hundred subjects were chosen on the basis of their commonalities: all subjects were required to be between the ages of 18 and 75, have a body mass index of 25 or higher and had to be free of any serious chronic disease. This original group of one hundred test subjects also excluded people who had recently taken certain medications, weight loss medications or supplements as well as other medical variables that have been shown to interfere with test results.

Once the one hundred original subjects were finalized, completely random selections were made from this group to establish two separate groups of fifty test subjects each. One of these groups would be the 'Placebo' or 'Control' group, and the other would be the 'Jen Fe' or 'Active' group. A placebo-controlled study is one in which the effects of a given variable, in this case the Jen Fe Next patch, are tested against the effects of a placebo, which is a variable for which there is known to be no effect.

In this study, the Jen Fe Next patch was compared to a placebo patch with only adhesive and no active ingredients. In addition to the placebo control, participants from both groups were given the same instructions for diet and exercise, to further eliminate variations between the two groups. All participants were instructed to follow a balanced diet between 1200 and 1500 calories per day, and to engage in regular exercise (approximately 30 minutes of walking each day).

A double-blind study is one in which neither the subjects being tested nor the persons administering testing are aware of the critical aspects of the experiment. The purpose of a double-blind study is to add yet another safeguard to protect the validity of test results. The result is a test that is free from any possible experimenter bias and what is known as the placebo effect (the idea that a test subject receiving a placebo may change their behavior based on what they believe the placebo is doing). Test subjects, both in the Control (Placebo) Group and in the Active (Jen Fe) Group were aware of little more than the fact that they were to follow certain guidelines with regard to diet and exercise, that they must follow specific instructions to apply an adhesive patch each day, and that they must keep a log of their activities related to each. The persons administering the evaluations of the test subjects were not aware of which participants were in the Control Group and which were in the Active Group.

All subjects were assessed a total of four times--once at the onset of the experiment, and at every subsequent 4-week interval for a total of 12 weeks. At each interval, all participants were objectively evaluated with identical equipment on the basis of total weight, body mass index, waist circumference and other key health variables. In addition, all subjects were also screened to ensure that the original criteria for participation had not changed-this included testing for the use of certain medications, pregnancy and other medical variables that could be a source of error in experimentation.

Ultimately, the Jen Fe Next patch passed this test of seemingly insurmountable scrutiny with an exceptional performance, particularly in the categories of weight and inches lost. In fact, when the 12-week assessments of both the Active (Jen Fe) Group and the Control (placebo) group were compared, the difference was remarkable. Jen Fe Next patch users lost an average of 68% more weight than those in the control group and lost an average of 44% more around the waist than those who wore the placebo patch.

In addition to a superb performance in both inches and weight lost, the study data demonstrates that the Jen Fe Next patch does not exude any of the adverse side affects that are common to many weight loss products. In fact, the data indicates that Jen Fe Next had no adverse effect on blood pressure, heart rate or respiratory rate.

In summary, the Jen Fe Next Clinical trial quantifies what so many already subjectively understood-that the Jen Fe Next patch is a very safe and effective product that, when used in combination with proper nutrition and exercise, can affect incredible weight loss results.


Baldvin (melimur Vantr) - 27/10/08 15:32 #

Textinn sem Helgi vitnar til er tekinn af heimasu framleiandans hrna svo ekki getur etta talist alveg h rannskn. g s ess heldur ekki merki a etta hafi veri birt ritrndu tmariti.

g leitai sngglega a "jen fe next" Google scholar, sciencedirect og PubMed en fann engar ritrndar greinar um etta. a ir auvita samt ekki a r su ekki til.


Jn Magns (melimur Vantr) - 27/10/08 15:40 #

Forslean is an extract from the herb Coleus Forskohlii, the manufacturer says it helps to mobilize fat and stimulate the thyroid.

ChromeMate is a natural form of chromium. The manufacturer says it has been shown to enhance energy levels, helping the body burn calories and promote weight-loss.

Guarana is a natural source of caffeine, which apparentlyhelps the body move fat out of storage and into the bloodstream, where it burns up as energy.

Fucus Vesiculosus, or Bladderwrack, is a marine algae which has been used as a homeopathic remedy for over 100 years to speed up metabolic rate and break down fatty tissues.

Ok, etta eru innihaldsefnin skv. einhverri vefsu sem g fann. Kemur kannski vart ef flk missi aeins meira vi a nota plsturinn ar sem a er Guarana honum.

Fucus Vesiculosus er annars hmopata"lyf", etta innihaldsefni er t.d. fullkomi kjafti. Hmopatalyf eru lyfleysur. Vi a sj etta segir mr eiginlega a um svikamyllu s a ra.

Eru einhverjar leibeiningar um matari sem fylgja plstrunum?

San finnst mr veri essu frnlegt, 7000kr fyrir svona plstur allt of miki. Hva borgai konan n fyrir etta v veri miast vi dollara?


Helgi D. - 27/10/08 15:51 #

Vi fengum reyndar mnaarskammt gefins af essu, til a prfa. Hn er allavega a ng me etta a hn tlar a halda fram.

Hn fkk engar leibeiningar varandi matarri ea slkt, geri ekki neitt ruvsi nema a nota plsturinn


Brynjlfur orvararson (melimur Vantr) - 27/10/08 21:21 #

Fucus Vesiculosus snist mr vera a sem vi kllum "sl", etta er bara venjulegur fjruari. a er hgt a kaupa hann urrkaan Natni og a er mjg gmul hef fyrir v a hann virki sem megrunarlyf og einnig gegn blgum miskonar. etta hefur hins vegar ekki veri sannreynt vsindalega. Wikipedia er me gtis grein um etta. Japanir ta etta grimmt, eir vera manna langlfastir og eru vst grannir upp til hpa .a. ekki getur etta skaa!

Coleus Forskohlii er jurt sem inniheldur efni forskolin (aftur er Wikipedia me gtis grein). etta efni hefur a v er virist vel ekkt hrif frumustarfsemi, eykur framleislu cyclic adenosin mnofosfats sem hefur mjg vtk hrif frumu-level en kannski ekki eins vel rannsaka hvaa hrif a hefur lkamann heild. rannskn virist koma ljs a forskolin auki vvamassa og teststern framleislu og v er a markasett til vaxtarktarmanna. Wikipedia nefnir msa ara mgulega virkni forskolin.

Forskolin hefur auk ess, eins og kaffein, svo kllu "lipolysis" hrif sem geta auki losun fitu r fitufrumum. Hvort au geri a raun er svo anna ml

Krm er nausynlegt lkamanum en a er yfirleitt ng af v dkku grnmeti og grfu korni. Einnig sl. Ofneysla krms er talin httuleg.

Helgi, g myndi benda konunni a kaupa sr poka af sl Natni (ea einhverri heilsubinni) og f sr sm hverjum degi. San er hgt a nlgast forskolin einhverri lkamsrktarstinni - og rakvl leiinni.

sjlfu sr er alveg hugsanlegt a essi efni hjlpi til vi fitulos en slkt hefur ekki veri rannsaka af hlutlausum aila. Bara a eitt a etta skuli vera plstri vekur grunsemdir, a er flki a koma lyfjum annig form a au smjgi gegnum skinn.

Veri er frnlega htt og sluaferin er auvita svindl eins og greinin bendir .

Sem sagt: F sr sl hverjum degi, bora grft brau og dkkt grnmeti og kannski grnt te til a skola v niur. tti a gera sama gagn og kostar ekki nema brotabrot.


Jn Frmann - 27/10/08 23:50 #

ari, allar gerir. Eru ekkert nema rungar sem lifa saman hpum. etta er v ekkert nema plntur sem flk er a bora urrka. Gerir lklega sama gagn og anna grnmeti ef etta er bora.

g hef enga tr v a essir plstar virki nokkurn skapaan hlut. Konan n er lklega a upplifa slrn hrif me notkun plstrana.

http://en.wikipedia.org/wiki/Seaweed


Helgi D. - 28/10/08 08:29 #

a m samt vel vera, en fyndi ar sem skoti var mig fyrir a vitna ekki neina rannskn gerir a sama, tlar a hn lklega a upplifa slrn hrif, n ess a styjast vi neitt :)

Mr finnst samt trlegt a slmir verkir hennar (sem stafa einnig af gigt) hafi bara horfi vegna einhverjar slrnnar upplifunar. a sem mestu mli skiptir er a verkirnir hurfu og hafa ekki komi aftur san hn byrjai a nota , a kemur svo ljs nna eftir 2 daga hvort eir komi aftur ar sem ess skammtur sem hn fkk gefins er a klrast...


Reynir (melimur Vantr) - 28/10/08 08:41 #

vsindalegum rannsknum er tvennt mikilvgt, reianleiki og rttmti. htt er a fullyra a reianleiki niurstana er ltill egar aeins er mld virkni efnis 50 manns. hrif lyfja eru mld sundum manna.

Eftirfarandi texti er bersnilega auglsingaskrum, ekki vsindalegar niurstur:

Ultimately, the Jen Fe Next patch passed this test of seemingly insurmountable scrutiny with an exceptional performance...

Og niursturnar eru besta falli ljsar:

Jen Fe Next patch users lost an average of 68% more weight than those in the control group and lost an average of 44% more around the waist than those who wore the placebo patch.

Hversu miki grenntust eir sem fengu lyfleysu? Magni vantar. Lttust eir um 1 kg a mealtali og eir plstrunum um 1,7 kg, ea voru tlurnar 10 kg og 17 kg? a skiptir mli egar kveur a verja sundum krna, hefi g haldi.

Svo er a naglaspuhrifin:

when used in combination with proper nutrition and exercise, can affect incredible weight loss results.

Nagli er kngafi, s btt spuna grnmeti og kjti.


Kristinn - 28/10/08 12:06 #

Helgi, ertu alveg viss a srt ekki a selja essa plstra?


Helgi D. - 28/10/08 13:26 #

J g bei eftir essu kommenti, j g er EKKI a selja essa plstra, hef ekki einu sinni prfa etta sjlfur. g vildi bara blanda mr essa umru ar sem konan hefur reynslu af essum plstri og hefur raun breytt lfi hennar essar rmu 3 vikur sem hn hefur veri essu.

Mr finnst frekar reytt egar flk dmir hlutina n ess a hafa neitt bakvi a, hafa ekki einu sinni prfa a sjlft. Hvort sem a su plstrarnir sem eru a hafa essi hrif lan hennar ea hn a upplifa slrn hrif eins og Jn Frmann bendir allavega lsir hn essi sem allt ru lfi.....svo geta menn auvita endalaust rasa um hvort s stan.


ttar - 28/10/08 15:41 #

Helgi D. bendir a flk ekki a dma hluti nema a prfa . M g ekki fordma hern n ess a prfa a ? Og a g mundi prfa plsturinn og finnast hann virka, er a langt fr v a vera snnun fyrir gti plstursins.

Nokkrar stur geta legi bakvi bata konu innar. Tkum dmi um kjklingaspuna frgu; ef ert duglegur a bora kjklingaspu egar ert kvefaur batnaru fyrr. Bregst aldrei ! a er v "fyrr" er ekki skilgreint og ll kvef htta einhvern tman. egar konan n fr verki ganga eir vntanlega yfir, eir semsagt koma og fara. Er ekki mguleiki a plsturinn hafi akkrat hitt ann tma ar sem verkurinn er a fara.

Annars vona g a konan n ni sr og li sem best. Einnig r Helgi minn, mundu bara a kaupa ekki hva sem er og halda gagnrnni hugsun.


Helgi D. - 28/10/08 16:26 #

a er margt til essu hj r ttar, svo a dmi um herini s gtt a mrgu leyti finnst mr a ekki sambrilegt, ar sem ert a bera saman fkniefni annars vegar og svo heilsuplstur hins vegar.

essi verkir hafa hrj hana mrg r rauninni, sama vi um mir hennar og svo mmu. Eftir barnsbur hafa verkirnir komi mun meiri mli, eftir einhver smvegis "tk" blossa eir vinlega upp. Vanalega koma eir upp oft hverri viku, aldrei hafa eir horfi eins og n, rmar rjr vikur. Kannski vill svo skemmtilega til a verkirnir hafa bara horfi nkvmlega sama tma og hn byrjai a prfa essa plstra, a verur v forvitnilegt a sj hva gerist egar hn klrar mnaarskammtinn.

g ver seint sakaur um a tra llu sem g heyri, enda hafi g litla sem enga tr essu egar hn fkk ennan prufu mnu.

A sjlfsgu maur ekki a gleypa vi llu, v miur eru alltof margir sem gera a...

Annars gaman a heyra mismunandi sjnarhorn essu, lfi vri ekkert skemmtilegt ef allir vru smu skoun er a nokku.

En haldii fram me essa mgnuu su! Kem oft vi hrna, mjg skemmtileg og hugaver lesning


Siggi - 28/10/08 18:29 #

Getur tskrt mekansma fyrir ennann dularfulla bata? Og skilur a vitnisburur er sjaldan talinn undir empirsk snnunarggn, ekki satt?

Loka hefur veri fyrir athugasemdir vi essa frslu. Vi bendum spjalli ef i vilji halda umrum fram.